Fundraising Fox

RAPT Therapeutics

5 known investors

rapt.com ↗

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases. Its pipeline includes ozureprubart, a long-acting anti-IgE antibody being developed for food allergy.

BiotechHealthtech

Investors · 5

Frazier Life SciencesPalo Alto
Kleiner PerkinsMenlo Park · $500K – $15M
Solasta VenturesBoston
The Column GroupSan Francisco · $30M
OrbiMedreportedNew York · $1M – $75M

Funding

SEC filings, press & company announcements
  • Undisclosed amountprivate placementDec 2024
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

RAPT Therapeutics Partners with Jemincare and Secures Funding - TipRanks.comtipranks.com · Dec 2024RAPT Therapeutics Secures Massive $150M Private Placement Led by Healthcare Investment Giants | RAPT Stock Newsstocktitan.net · Dec 2024RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September - RAPT Therapeuticsrapt.com · Sep 2023

Frequently asked questions

What does RAPT Therapeutics do?
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases. Its pipeline includes ozureprubart, a long-acting anti-IgE antibody being developed for food allergy.
Who are RAPT Therapeutics's investors?
RAPT Therapeutics's investors include Frazier Life Sciences, Kleiner Perkins, Solasta Ventures, The Column Group, OrbiMed.